期刊文献+

生物制药的专利保护和权利平衡 被引量:2

On the Patent Protection and Balance of Rights in the Biopharmaceutics
下载PDF
导出
摘要 生物技术蓬勃发展并作用于医药领域,形成了全新的生物制药产业。在生物制药下发明和发现的区别变得模糊,传统专利制度受到了很大冲击,现实要求对生物制药也进行专利保护。对生物制药领域知识产权保护的制高点基因专利保护而言,涉及到两个平衡问题:一是国家间的基因资源利益的平衡;二是研究者利益、产业利益和社会公共利益的平衡。 The flourishing development of biotechnology and its function in the medicine field have resulted in a wholly-new pharmaceutics industry—biopharmaceutics. In the biopharmaceutic environment, the distinction between invention and discovery becomes unclear,which has a severe impact on the traditional patent system. It is required to give patent protection to the biopharmaceutics in view of the practical need. As to the patent protection of gene, which is the top point of the intellectual protection in biopharmaceutics, there are two issues of balance;one of the interests in gene resource among different states;and the other is the balance of economic interests among the researchers, the industrial investors and the public.
作者 吴仁坚
机构地区 中国政法大学
出处 《柳州师专学报》 2008年第2期67-70,共4页 Journal of Liuzhou Teachers College
关键词 生物技术 生物制药 基因 专利 权利平衡 biotechnology biopharmaceutics gene patent balance of rights
  • 相关文献

参考文献11

二级参考文献10

共引文献25

同被引文献21

  • 1宋华琳.中美两国药品加速审评程序之比较分析[J].中国医药技术经济与管理,2007,1(5):6-11. 被引量:3
  • 2姚维保.我国生物技术与新医药产业专利保护:现状、问题与可持续创新战略[J].科技管理研究,2005,25(9):20-23. 被引量:11
  • 3张宇燕.经济发展与制度选择[M].北京:经济科学出版社,1992. 被引量:1
  • 4高辉.生物类似物法规的"中国式"思维[EB/OL].(2014-10-07).http://www.dxy.cn/bbs/topic. 被引量:1
  • 5任彦.欧洲死亡人数的77%源于慢性病暴露其医保制度弊端[N].人民日报,2015-01-06(21). 被引量:1
  • 6MULLER RH, KECK CM. Challenges and solutions for the de- livery of biotech drugs - a review of drug nanocrystal technology and lipid nanoparticles [ J ]. J Biotechnol, 2004,1 ( 113 ) : 151 - 170. 被引量:1
  • 7AAPRO M, MONFARDINI S, JIRILLO A, et al. Management of primary and advanced breast cancer in older unfit patients ( medi- cal treatment) [ J]. Cancer Treat Rev ,2009 ,35 (6) :503 - 508. 被引量:1
  • 8THAKRAR K, BODALIA P, GROOSO A. Assessing the efficacy and safety of Omnitrope[ J]. Br J Clin Pharm, 2010, 13(2) : 298 - 301. 被引量:1
  • 9European Medicine Agency, European Public Assessment Report (EPAR) for Binocrit [ EB/OL]. (2008 - 10 - 23 ). http:// www. ema. europa, eu/docs/en_GB/document_library/EPAR_- Assessment_Report_-_Variation/buman/OOO725/WC500053679. 被引量:1
  • 10KROLL D. FDA Approves First US Biosimilar; Hold Your Breath On Cost Savings [ EB/OL ]. ( 2015 - 03 - 06 ). http ://www. for- bes. com/sites/davidkroll/2015/03/06/fda-approves-first -us-bio- similar-zarxio-by-sandoz/3/. 被引量:1

引证文献2

二级引证文献6

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部